A
Aspen Neuroscience
Biotechnology company that uses innovative genomic approaches combined with stem cell biology
About Aspen Neuroscience
Aspen Neuroscience, Inc., headquartered in San Diego, is a private biotechnology company specializing in personalized cell therapies for Parkinson's disease. The company leverages advanced stem cell biology and genomics to develop patient-specific treatments aimed at reversing the effects of the disease. Aspen Neuroscience operates in the healthcare and biotechnology market, primarily serving patients diagnosed with Parkinson's disease. The company's business model revolves around developing and commercializing its proprietary induced pluripotent stem cell (iPSC) platform, which combines cutting-edge artificial intelligence and genomic technologies. Revenue is generated through partnerships, licensing agreements, and potentially future sales of its cell therapy products. The company is in the development stage, focusing on research and clinical trials to bring its innovative therapies to market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Diego, United States
- Employees
- 127
- Open positions
- 13
- Dealroom signal
- 76.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Degenerative Diseases, Chronic Disease, Regenerative Medicine, Precision Medicine, Spinout, Biotech and Pharma, Cell Therapy, Woman Founder
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Nov 2025 | $115M | $738M | Kite Pharma · Section 32 · Lifeforce Capital · Medical Excellence Capital | — |
| GRANTOther financing | May 2024 | $8M | — | California Institute for Regenerative Medicine | ↗ |
Growth signals
Latest recorded traffic for Aspen Neuroscience is 4.4K monthly website visits, down 26.7% over the last three months. Aspen Neuroscience's team grew 3.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Domain Associates
Alexandria Venture Investments
ARCH Venture Partners
OrbiMed
Section 32
Axon Ventures
California Institute for Regenerative Medicine
Series A11 investors entered at this stage
Frazier Healthcare Partners
GV
LYFE Capital
Revelation Partners- TCTimefolio Capital
Medical Excellence Capital
EDBI
Mirae Asset Capital
Sam Altman
Newton Investment Management
Lifeforce Capital
Series B and later6 investors entered at this stage
Silicon Valley Bank
Frazier Life Sciences
Kite Pharma
The Conrad Prebys Foundation
Cormorant Asset Management
Balyasny Asset Management
Other known investors1 additional known investor
Scripps Translational Science Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aspen Neuroscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aspen Neuroscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.